Iannone Robert's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 7, 2025
- Accession no.
- 0001765581-25-000026
- Filed
- Mar 7, 2025
- Trade date
- Mar 5-7, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $981.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Iannone RobertCIK 0001737329 | Officer (EVP, Global Head of R&D & CMO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | Ordinary Shares | DReturned to the companyDisposed | −5,239 | $138.95 | −$727,959.05 | 89,104 | Direct | |
| Mar 7, 2025 | Ordinary Shares | SSaleDisposed | −5,532 | $138.21F3 | −$764,577.72 | 83,572 | Direct | |
| Mar 7, 2025 | Ordinary Shares | SSaleDisposed | −1,548 | $140.00 | −$216,720 | 82,024 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.19 to $138.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.